ArticleFrontiers in oncology2021

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers.

Atsuto Mouri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.